Literature DB >> 23153106

Patient-maintained propofol sedation using reaction time monitoring: a volunteer safety study.

S Allam1, K J Anderson, C O'Brien, J A Macpherson, S Gambhir, J A Leitch, G N C Kenny.   

Abstract

Previous volunteer studies of an effect-site controlled, patient-maintained sedation system using propofol have demonstrated a risk of over-sedation. We have incorporated a reaction-time monitor into the handset of the patient-maintained sedation system to add an individualised patient-feedback mechanism. This study assessed if such reaction-time feedback modification would reduce the risk of over-sedation in 20 healthy volunteers deliberately attempting to over-administer themselves propofol. All the volunteers successfully sedated themselves without reaching any unsafe endpoints. All volunteers maintained verbal contact throughout, in accordance with the definition of conscious sedation. The mean (SD) lowest S(p) O(2) was 97 (1.7) % when breathing room air and no volunteer required supplementary oxygen. The mean (SD) maximum effect-site propofol concentration reached was 1.7 (0.4) μg.ml(-1) . The present system was found to be safer than its predecessors, allowing conscious sedation, but preventing over-sedation. Anaesthesia
© 2012 The Association of Anaesthetists of Great Britain and Ireland.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23153106     DOI: 10.1111/anae.12036

Source DB:  PubMed          Journal:  Anaesthesia        ISSN: 0003-2409            Impact factor:   6.955


  2 in total

1.  Clinical application of a novel endoscopic mask: A randomized controlled trial in aged patients undergoing painless gastroscopy.

Authors:  Guangyu Cai; Zhenling Huang; Tianxiao Zou; Miao He; Shanjuan Wang; Ping Huang; Bin Yu
Journal:  Int J Med Sci       Date:  2017-02-08       Impact factor: 3.738

2.  A Prototype Patient-Maintained Propofol Sedation System Using Target Controlled Infusion for Primary Lower-Limb Arthroplasty.

Authors:  James Sprinks; Frank Worcester; Philip Breedon; Paul Watts; David Hewson; Nigel Bedforth
Journal:  J Med Syst       Date:  2019-06-26       Impact factor: 4.460

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.